Panoply™ Human LILRB1 Knockdown Stable Cell Line

Although 60%-70% of patients with diffuse large B-cell lymphoma (DLBCL) are curable with current standards of chemotherapy and immunotherapy, the remainder develop treatment resistance and experience poor clinical outcomes. More effective DLBCL treatment strategies are needed. Here, researchers analyzed a clinical patient database to investigate the potential function of leukocyte immunoglobulin-like receptor B1 (LILRB1) in DLBCL. They found that LILRB1 is highly expressed in DLBCL cells and negatively correlated with overall survival in DLBCL patients. Knockdown of LILRB1 effectively inhibited DLBCL cell proliferation in vitro and in vivo. Mechanistically, LILRB1 upregulates CREB/CREB phosphorylation and transactivates SORBS3 expression to maintain DLBCL cell proliferation and tumorigenicity. LILRB1 is highly expressed in DLBCL cells and negatively correlated with patient survival. Furthermore, researchers identified a role for the LILRB1-CREB-SORBS3 pathway in maintaining DLBCL cell proliferation. These data suggest that LILRB1 may be a potential therapeutic target for DLBCL.

The researchers confirmed the role of LILRB1 in lymphoma development in vivo by subcutaneously injecting LILRB1-knockdown Raji cells into NOD-SCID mice. Mice were sacrificed, and tumor size was photographed and measured four weeks later (Figure 1A). Surprisingly, tumors generated by LILRB1-knockdown Raji cells were much smaller in size and weight than those generated by scrambled-sequence cells (Figures 1B-C). Similarly, LILRB1-knockdown Su-DHL4 cells grew much more slowly in vivo than cells infected with the scrambled sequence (Figures 1D-F). These findings indicate that LILRB1 promotes lymphoma cell proliferation in vivo.

Figure 1. LILRB1 enhanced lymphoma development in vivo. (Cao L, et al., 2025)